Company Filing History:
Years Active: 2008
Title: David Alan Playford: Innovator in Cardiovascular Treatment
Introduction
David Alan Playford is a notable inventor based in Perth, Australia. He has made significant contributions to the field of medicine, particularly in the treatment of cardiovascular diseases. His innovative approach combines established compounds to address critical health issues.
Latest Patents
David Alan Playford holds a patent for a unique combination of fenofibrate and coenzyme Q10 aimed at treating endothelial dysfunction. This invention relates to the use of a peroxisome proliferator-activated receptor (PPAR) activator and a benzoquinone to treat and prevent disorders characterized by endothelial dysfunction, such as cardiovascular disease, strokes, and myocardial infarction. The preferred embodiment of this invention utilizes coenzyme Q10 as the benzoquinone and fenofibrate as the PPAR activator. He has 1 patent to his name.
Career Highlights
Throughout his career, Playford has been associated with Fournier Laboratories Ireland Limited, where he has contributed to various research initiatives. His work focuses on developing effective treatments for cardiovascular conditions, showcasing his commitment to improving patient outcomes.
Collaborations
David Alan Playford has collaborated with Gerald Francis Watts, enhancing the research and development efforts within his field. Their partnership has led to advancements in understanding and treating cardiovascular diseases.
Conclusion
David Alan Playford's innovative work in combining fenofibrate and coenzyme Q10 represents a significant advancement in the treatment of endothelial dysfunction. His contributions continue to impact the medical field positively, highlighting the importance of innovation in healthcare.